ArticleFrontiers in microbiology2018
Design, Synthesis and Evaluation of Branched RRWQWR-Based Peptides as Antibacterial Agents Against Clinically Relevant Gram-Positive and Gram-Negative Pathogens.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- A Comprehensive Review of Nanoparticles in the Fight Against Antimicrobial Resistance.Pathogens (Basel, Switzerland) · 2025Pooled it
- Targeting Resistance Vulnerabilities of Clinical ESKAPE Isolates Using Lactoferrin and Its Functional Fragments.Current microbiology · 2026Article
- Building a Simple Platform for Tailoring Peptide Surface Chemistry to Enhance Cellular Uptake of Polymer-Coated Gold Nanoparticles.ACS omega · 2026Article
- Fluorescent Peptides Internalize HeLa Cells and Kill Multidrug-Resistant Clinical Bacterial Isolates.Antibiotics (Basel, Switzerland) · 2025Article
- Cationic antimicrobial peptides: potential templates for anticancer agents.Frontiers in medicine · 2025Review
- Design and Evaluation of Short Bovine Lactoferrin-Derived Antimicrobial Peptides against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial effect and mechanism of bovine lactoferrin against the potato common scab pathogen Streptomyces scabiei.PloS one · 2022Article
- Secondary Structural Transformation of Bovine Lactoferricin Affects Its Antibacterial Activity.Probiotics and antimicrobial proteins · 2021Article
- Furan-Conjugated Tripeptides as Potent Antitumor Drugs.Biomolecules · 2020Article
- Pullulan nanofibers containing the antimicrobial palindromic peptide LfcinB (21-25)RSC advances · 2019Article
- Synergistic bactericide and antibiotic effects of dimeric, tetrameric, or palindromic peptides containing the RWQWR motif against Gram-positive and Gram-negative strains.RSC advances · 2019Article
- Effect of Polyvalence on the Antibacterial Activity of a Synthetic Peptide Derived from Bovine Lactoferricin against Healthcare-Associated Infectious Pathogens.BioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance of pathogenic bacteria has become a public health crisis that requires the urgent design of new antibacterial drugs such as antimicrobial peptides (AMPs). Seeking to obtain new, lactoferricin B (LfcinB)-based synthetic peptides as viable early-stage candidates for future development as AMPs against clinically relevant bacteria, we designed, synthesized and screened three new cationic peptides derived from bovine LfcinB. These peptides contain at least one RRWQWR motif and differ by the copy number (monomeric, dimeric or tetrameric) and structure (linear or branched) of this motif. They comprise a linear palindromic peptide (RWQWRWQWR), a dimeric peptide (RRWQWR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.